A Randomised, Assessor-blind, Placebo and Active Controlled, Parallel Group Study to Assess the Phototoxic Potential of Faldaprevir (Administered Orally, Once Daily) for 6 Days in Healthy Male and Female Subjects

Trial Profile

A Randomised, Assessor-blind, Placebo and Active Controlled, Parallel Group Study to Assess the Phototoxic Potential of Faldaprevir (Administered Orally, Once Daily) for 6 Days in Healthy Male and Female Subjects

Withdrawn prior to enrolment
Phase of Trial: Phase I

Latest Information Update: 31 Jul 2014

At a glance

  • Drugs Faldaprevir (Primary) ; Ciprofloxacin
  • Indications Hepatitis C
  • Focus Adverse reactions
  • Sponsors Boehringer Ingelheim
  • Most Recent Events

    • 24 Jun 2014 Status changed from recruiting to withdrawn prior to enrolment as reported by ClinicalTrials.gov.
    • 30 Apr 2014 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.
    • 21 Apr 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top